Myasthenia gravis market to grow to $13 billion in 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 11.1% from $4.5 billion in 2024 to $13.0 billion in 2034, according to intelligence platform GlobalData.
GlobalData’s report, “Myasthenia Gravis – Opportunity Assessment and Forecast - Update,” reveals that growth will primarily be driven by an increase in diagnosed prevalence; the approval of argenx’ (Euronext & Nasdaq: ARGX) Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) and Vyvgart hytrulo across all MG subtypes; and the introduction of six late-stage pipeline products: telitacicept, Descartes-08, cemdisiran monotherapy, pozelimab + cemdisiran combination therapy, cladribine capsules, and gefurulimab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze